Subscribe to our PDX mailing list

* indicates required

Relevant Preclinical Models

Patient derived xenograft (PDX) tumor models emerged as a new approach for preclinical testing of novel anticancer compounds in vivo due to its preservation of key features, which includes invasiveness, stromal reaction, tumor vasculature and cellular diversity of human carcinomas. In contrast to a cell line-xenograft tumor model, PDX tumors are established from the transplantation of fresh tumor tissue from a cancer patient into a immunodeficient mouse.

Breast
PDX ID Patient Age Patient Sex
NUBC01
NUBC02 39 Female
NUBC03
NUBC04 67 Female
NUBC05 47 Female
NUBC06 38 Female
NUBC07 46 Female
AML
PDX ID Patient Age Patient Sex
NUAML01 37 Femal
Bladder
PDX ID Patient Age Patient Sex
NUBCA01 76 Male
NUBCA02 71 Male
NUBCA03 85 Male
NUBCA04 71 Male
Colon
PDX ID Patient Age Patient Sex
NUCRC01 86 Female
NUCRC02 61 Female
NUCRC03
Endometrial
PDX ID Patient Age Patient Sex
NUEC178 Female
Glioblastoma
PDX ID Patient Age Patient Sex
NUGBM01 49 Male
NUGBM02 65 Female
NUGBM03
NUGBM04
NUGBM05
NUGBM06
NUGBM07
NUGBM08
NUGBM09
NUGBM010
Liver
PDX ID Patient Age Patient Sex
NUHCC01 71 Female
Lung
PDX ID Patient Age Patient Sex
NUPELC01 79 Male
Mesothelioma
PDX ID Patient Age Patient Sex
NUPEMC01
NUPEMC02 63 Male
Multiple Myeloma
PDX ID Patient Age Patient Sex
NUMM01

Ovarian
PDX ID Patient Age Patient Sex
NUOVCA4 Female
NUOVCA5 Female
NUOVCA6 Female
NUOVCA7 Female
NUOVCA8 Female
NUOVCA9 Female
NUOVCA10 Female
NUOVCA12 Female
NUOVCA13 Female
Pancreatic
PDX ID Patient Age Patient Sex
NUPDAC01 62 Male
NUPDAC02 68 Female
NUPDAC03 60 Male
NUPDAC04
NUPDAC05
NUPDAC06
NUPDAC07
NUPDAC09